T1 and T2 Mapping in Uremic Cardiomyopathy: An Update.

IF 4.2 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiac Failure Review Pub Date : 2022-01-18 eCollection Date: 2022-01-01 DOI:10.15420/cfr.2021.19
Luca Arcari, Giovanni Camastra, Federica Ciolina, Massimiliano Danti, Luca Cacciotti
{"title":"T<sub>1</sub> and T<sub>2</sub> Mapping in Uremic Cardiomyopathy: An Update.","authors":"Luca Arcari,&nbsp;Giovanni Camastra,&nbsp;Federica Ciolina,&nbsp;Massimiliano Danti,&nbsp;Luca Cacciotti","doi":"10.15420/cfr.2021.19","DOIUrl":null,"url":null,"abstract":"<p><p>Uremic cardiomyopathy (UC) is the cardiac remodelling that occurs in patients with chronic kidney disease (CKD). It is characterised by a left ventricular (LV) hypertrophy phenotype, diastolic dysfunction and generally preserved LV ejection fraction. UC has a major role mediating the increased rate of cardiovascular events, especially heart failure related, observed in patients with CKD. Recently, the use of T<sub>1</sub> and T<sub>2</sub> mapping techniques on cardiac MRI has expanded the ability to characterise cardiac involvement in CKD. Native T<sub>1</sub> mapping effectively tracks the progression of interstitial fibrosis in UC, whereas T<sub>2</sub> mapping analysis suggests the contribution of myocardial oedema, at least in a subgroup of patients. Both T<sub>1</sub> and T<sub>2</sub> increased values were related to worsening clinical status, myocardial injury and B-type natriuretic peptide release. Studies investigating the prognostic relevance and histology validation of mapping techniques in CKD are awaited.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":" ","pages":"e02"},"PeriodicalIF":4.2000,"publicationDate":"2022-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/ad/cfr-08-e02.PMC8790724.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiac Failure Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/cfr.2021.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 6

Abstract

Uremic cardiomyopathy (UC) is the cardiac remodelling that occurs in patients with chronic kidney disease (CKD). It is characterised by a left ventricular (LV) hypertrophy phenotype, diastolic dysfunction and generally preserved LV ejection fraction. UC has a major role mediating the increased rate of cardiovascular events, especially heart failure related, observed in patients with CKD. Recently, the use of T1 and T2 mapping techniques on cardiac MRI has expanded the ability to characterise cardiac involvement in CKD. Native T1 mapping effectively tracks the progression of interstitial fibrosis in UC, whereas T2 mapping analysis suggests the contribution of myocardial oedema, at least in a subgroup of patients. Both T1 and T2 increased values were related to worsening clinical status, myocardial injury and B-type natriuretic peptide release. Studies investigating the prognostic relevance and histology validation of mapping techniques in CKD are awaited.

Abstract Image

尿毒症心肌病T1和T2定位:最新进展。
尿毒症心肌病(UC)是发生在慢性肾脏疾病(CKD)患者的心脏重构。其特征是左室肥厚表型、舒张功能障碍和左室射血分数普遍保留。UC在CKD患者心血管事件发生率的增加中起主要作用,尤其是与心力衰竭相关的心血管事件。最近,在心脏MRI上使用T1和T2制图技术扩大了表征CKD中心脏受累的能力。原生T1定位有效地跟踪UC间质纤维化的进展,而T2定位分析提示心肌水肿的贡献,至少在一个亚组患者中。T1、T2升高均与临床状况恶化、心肌损伤及b型利钠肽释放有关。CKD的预后相关性研究和组织学验证有待进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
31
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信